Key Takeaways
- Bank of England policymaker Alan Taylor warns of a potential inflation undershoot, signaling that two to three more interest rate cuts may be required to reach a neutral level.
- Gilead Sciences (GILD) has entered a definitive agreement to acquire Arcellx (ACLX) for an implied equity value of $7.8 billion, paying $115 per share in cash to secure full control of the promising cancer therapy Anito-cel.
- Merck (MRK) is reorganizing its human health business into two separate divisions to protect its portfolio ahead of the 2028 patent expiration for its blockbuster cancer drug, Keytruda.
- Domino’s Pizza (DPZ) reported Q4 revenue of $1.54 billion, surpassing analyst estimates of $1.52 billion, driven by 3.7% U.S. same-store sales growth.
- EU Trade Commissioner Maroš Šefčovič is meeting with G7 trade ministers to address a "permanent" U.S. high-tariff regime that officials expect to impact global trade for years.
BoE Signals Shift Toward Rate Normalization
Bank of England (BoE) policymaker Alan Taylor stated Monday that the risks to the UK economy are shifting from persistent inflation to a potential inflation undershoot and rising cyclical unemployment. Taylor noted that he has become more reassured that inflation is normalizing at a reasonable pace, though he cautioned that services CPI remains a slight concern after failing to fall as quickly as hoped.
The central bank official indicated that the BoE is approaching a neutral interest rate level but is "not there yet," suggesting that two or three additional rate cuts are likely on the horizon. Taylor also warned that the U.S. high-tariff regime is "here to stay" and represents a multi-year trade shock that the bank must monitor closely.
Gilead Bolsters Oncology Portfolio with $7.8B Acquisition
Gilead Sciences (GILD) announced a major expansion of its cell therapy footprint by agreeing to acquire its partner Arcellx (ACLX). Under the terms of the deal, Gilead will pay $115 per share in cash, a significant premium that values the biotech firm at approximately $7.8 billion. Shareholders are also eligible for a $5 per share contingent value right (CVR) based on future sales milestones.
The acquisition gives Gilead full control over Anito-cel, a late-stage CAR T-cell therapy for relapsed or refractory multiple myeloma. The deal is expected to be accretive to earnings per share (EPS) starting in 2028, as it eliminates future milestone and royalty payments previously owed under their 2022 collaboration agreement.
Merck Restructures Ahead of Keytruda Patent Cliff
Merck (MRK) is proactively overhauling its leadership and corporate structure by splitting its human health business into two distinct units. One division will focus exclusively on oncology, housing the blockbuster drug Keytruda, while the second will manage specialty pharmaceuticals, vaccines, and infectious diseases.
The reorganization is a strategic move to mitigate the impact of the 2028 loss of U.S. market exclusivity for Keytruda, which currently accounts for nearly half of the company's total sales. By separating these units, Merck aims to sharpen its focus on its internal pipeline and diversify its revenue streams before lower-priced biosimilar competition enters the market.
Domino’s Beats Estimates with "Hungry for MORE" Strategy
Domino’s Pizza (DPZ) delivered a strong fourth-quarter performance, reporting revenue of $1.54 billion against the $1.52 billion expected by Wall Street. The company saw U.S. same-store sales grow by 3.7%, while international same-store sales increased by 0.7%, marking a 32nd consecutive year of international growth.
CEO Russell Weiner attributed the results to the company's "Hungry for MORE" strategy, which emphasizes menu innovation and digital platform upgrades. Despite the revenue beat, the company’s net income of $181.6 million was slightly below the $182.3 million consensus estimate, though the board approved a 15% increase in the quarterly dividend to $1.99 per share.
EU Navigates Trade Volatility and Ukraine Aid
The European Union is seeking a return to "stability and predictability" as it grapples with new 15% global tariffs proposed by the U.S. administration. Commissioner Maroš Šefčovič is scheduled to meet with G7 trade ministers and EU envoys to discuss a coordinated response to the trade shock, which has already led to the freezing of some ratification processes for transatlantic trade deals.
Separately, the EU Commission is putting pressure on Hungary’s PM Viktor Orban to honor political commitments regarding a €90 billion loan to Ukraine. Officials warned that failing to respect the agreement would constitute a "breach of loyal cooperation," even as Ukraine reported restoring control over 400 square kilometers of territory in its latest military offensive.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.